Advertisement

Heterogeneity of antigen expression in advanced epithelial ovarian cancer

      This paper is only available as a PDF. To read, Please Download here.

      Summary

      Immunohistochemical techniques were used to evaluate the expression of six antigens (CA 125, TAG 72, CA 19-9, 0VTL3, DF3, and transferrin receptor) in frozen sections from the primary tumor and metastases of 20 patients with epithelial ovarian cancer. Heterogeneous expression of most antigens was observed within a given tumor nodule, but in each patient the proportion of cells expressing an antigen was similar in the primary tumor and metastases. To explore the stability of the antigenic phenotype of individual cells, we studied CA 125 expression in an ovarian cancer cell line. Cells were separated into CA 125-positive and -negative groups using fluorescence-activated cell sorting. After the two groups of cells were recultured separately, only 38% of cells originally sorted as CA 125 positive still expressed CA 125, whereas 27% of cells sorted as CA 125 negative expressed CA 125. That cells may gain or lose CA 125 expression in culture suggests that expression of CA 125 by ovarian cancer cells is not a stable trait. (Am J Obstet Gynecol 1990;162:883-8.)

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Boyer CM
        • Lidor Y
        • Lottich SC
        • Bast Jr., RC
        Antigenic cell surface markers in human solid tumors.
        Antibody Immunoconjugates Radiopharmaceut. 1988; 1: 105-162
        • Bast Jr, RC
        • Klug TL
        • St John E
        • et al.
        A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.
        N Engl J Med. 1983; 309: 883-887
        • Berek JS
        • Knapp RC
        • Malkasian GD
        • et al.
        CA 125 serum levels correlated with second-look operations among ovarian cancer patients.
        Obstet Gynecol. 1986; 67: 685-689
        • Malkasian Jr, GD
        • Knapp RC
        • Lavin PT
        • et al.
        Preoperative evaluation of serum CA 125 levels in premenopausal and post-menopausal patients with pelvic masses: discrimination of benign from malignant disea.
        Am J Obstet Gynecol. 1988; 159: 341-346
        • Haisma HJ
        • Moseley KR
        • Battaile Al
        • Griffiths TC
        • Zurawski VR
        • Knapp RC
        Biodistribution, pharmacokinetics and imaging of 131I-labelled OC125 in ovarian cancer.
        Int J Cancer. 1988; 2 (suppl): 109-113
        • Fitzgerald DJ
        • Bjorn M
        • Ferris RJ
        • et al.
        Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer.
        Cancer Res. 1987; 47: 1407-1410
        • Boyer CM
        • Borowitz MJ
        • McCarty Jr, KS
        • et al.
        Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cells.
        Int J Cancer. 1989; 43: 55-60
        • Nuti M
        • Teramoto YA
        • Mariana-Constantini RM
        • Hand PH
        • Colcher D
        • Schlom J
        A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations.
        Int J Cancer. 1982; 29: 539-545
        • Thor A
        • Gorstein F
        • Ohuchi N
        • Szpak CA
        • Johnston WW
        • Schlom J
        Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3.
        JNCI. 1986; 76: 995-1003
        • Magnani JL
        • Nilsson B
        • Brockhaus M
        • et al.
        A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialyated lacto-N-fucopentaose II.
        J Biol Chem. 1982; 257: 14365-14369
        • Poels LG
        • Peters D
        • van Megen Y
        • et al.
        Monoclonal antibody against human ovarian tumor-associated antigens.
        JNCI. 1986; 76: 781-791
        • Sekine H
        • Ohno T
        • Kufe DW
        Purification and characterization of a high molecular weight glycoprotein detectable in human milk and breast carcinoma.
        J Immunol. 1985; 135: 3610-3615
        • Hayes DF
        • Skine S
        • Ohno T
        • Abe M
        • Keefe K
        • Kute DW
        Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients.
        J Clin Invest. 1985; 75: 1671-1678
        • Frankel AE
        • Ring DB
        • Tringale F
        • Hsieh-Ma ST
        Tissue distribution of breast cancer-associated antigen defined by monoclonal antibodies.
        J Biol Response Mod. 1985; 4: 273-286
        • Bast Jr, RC
        • Feeney M
        • Lazarus H
        • Nadler LM
        • Colvin RB
        • Knapp RC
        Reactivity of a monoclonal antibody with human ovarian cancer.
        J Clin Invest. 1981; 68: 1331-1337
        • Feizi T
        Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens.
        Nature. 1985; 314: 53-57
        • Rubin SC
        • Finstad C
        • Hoskins WJ
        • Federici M
        • Lloyd KO
        • Lewis Jr, JL
        A longitudinal study of antigen expression in epithelial ovarian cancer.
        Gynecol Oncol. 1989; 34: 389-394